Media & Technology
Flexible Solar Modules Pioneer ASTI (Ascent Solar); New Leadership, Major Investment, Tubsolar, Fortsch, Crowdex – Swift Runner
ASTI a pioneer in Flexible Solar Modules is making a powerful run up the charts in recent months from well under a penny in December to recent highs of $0.097 per share. The stock has quickly attracted legions of new shareholders and is transforming into a volume leader in small caps trading $35 million in dollar volume on Wednesday alone. ASTI is ex Nasdaq and we have been reporting on the Company for years; back in 2017 we said of ASTI: “OTC speculators love ex big board stocks for their ready liquidity and proven ability to make spectacular moves once on the bb’s and ASTI certainly has potential; this is a company that manufactures battery and solar integrated phone cases designed for Apple and Samsung smartphones that recently announced record revenues as well as a major breakthrough in power-to-weight ratio for its superlight solar modules.”
There are big things happening at ASTI, a Company at the right place at the right time as Solar Energy is currently seeing an enormous global boost. The Company recently received a $2.5 million investment from Bernd Fortsch via Crowdex, a well-known German entrepreneur worth hundreds of millions who has now become the controlling shareholder. Mr. Fortsch has quickly brought on a top-level management team of major international executives including Michael Gilbreth as CFO and Will Clarke as class 2 director. On January 4 ASTI received an additional $2,500,000 investment from publicly traded German Company TubeSolar AG, a developer of photovoltaic thin-film tubes that are assembled into modules to enable additional application opportunities in solar power generation compared to conventional solar modules, particularly in the agricultural sector. ASTI CEO Victor Lee stated: “This marks the closure of our Phase I reorganization plan and begins a new era for Ascent Solar. We will continue to strengthen our balance sheet as we ramp up production to serve Tier-1 specialty PV markets in conjunction with satisfying the future demand of TubeSolar.”
Ascent Solar Technologies, Inc., (ASTI: otc stock) develops, manufactures and sells solar solutions from bare modules to finished goods and everything in between. Ascent Solar owns a valuable patent portfolio including over 80 granted and pending patents. Headquartered in Thornton, Colorado) ASTI is a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) modules using flexible substrate materials that are more versatile and rugged than traditional solar panels. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine, and one of TIME Magazine’s 50 best inventions for 2011. The technology described above represents the cutting edge of flexible power and can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications.
ASTI’s award winning thin-film CIGS solar modules are more flexible, versatile and rugged than traditional solar panels. They use plastic as their substrate rather than glass that’s used by tradition rooftop solar panels. The Company diversified into consumer goods as they could not compete with the low-cost Chinese solar panels in the traditional electricity generating segment.
Microcapdaily has been reporting on ASTI for years ever since it was delisted from the big boards and trading well below $0.01. in 2017 we reported on ASTI stating: “ASTI was de-listed by the NASDAQ in February after the stock dipped below $1 level due to continued massive dilution. The Company recently affected a 1 for 20 reverse stock split that has ended with the stock hitting new lows once again. ASTI has tons of potential; this is a company that manufactures battery and solar integrated phone cases designed for Apple and Samsung smartphones that recently announced a major breakthrough in power-to-weight ratio for its super light solar module.”
That dilution we spoke of in 2017 is gone. In December we reported on the change of control via the Crowdex transaction described in 8k’s filed 12/04 and 12/28 whereby Crowdex became majority owner of ASTI. Bernd Förtsch whose net worth is several hundred million Euros is 100% ownder of Crowdex making him the majority shareholder in ASTI. Bernd Förtsch is a German entrepreneur and publisher. He is the founder and owner of the Kulmbach- based Börsenmedien AG, which publishes, among other things, the stock exchange and financial magazines The Shareholder and The Investor. In addition, Bernd Förtsch is founder and owner of Aktionär TV AG and founder of the online broker flatex . Förtsch achieved notoriety above all in the context of the stock market euphoria of the Neuer Markt. Mr. Förtsch is 60,3% owner of TubeSolar AG and he holds stakes in Companies such as BF Holding GmbH, Deposit Solutions GmbH, Flatex AG, the biggest online broker in Europe, valued at 1.2 billion Euros, Flatex Bank AG, Börsenmedien AG, Coreo AG, Fintech Group AG and many more.
As we stated above Ascent Solar owns a valuable patent portfolio including over 80 granted and pending patents and has achieved a major breakthrough in power-to-weight ratio for its superlight solar module, delivering over 1700 watts of power per kilogram, operating at AM0, technically known as the space environment. At this performance, Ascent’s superlight module would weigh 66% less than a comparable PV system using the highest-quality crystalline silicon and with far less design complexity. The elimination of two-thirds of the weight is a critical improvement for satellites, space vehicles and space stations. For space and near-space applications, power-to-weight ratio is a key performance metric. In addition to simplicity, the Company’s modules could dramatically impact cost. Depending on the application, such as low earth orbit all the way to manned flights, including contemplated missions to Mars, the fully burdened cost can be anywhere from thousands of dollars to $1 Million per pound for a space launch. By creating this superior module with the best power-to-weight ratio of any available product, Ascent has enabled entrance into the rapidly growing space and near space markets.
To Find out the inside Scoop on ASTI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On January 6 ASTI announced the completion of Tranche 2 of the Series 1A Preferred Stock. On September 22, 2020, the Company entered into a securities purchase agreement (“Series 1A SPA”) with Crowdex Investment LLC, a private investor and sold 2,000 shares of Series 1A Preferred Stock to Crowdex in exchange for $2,000,000 of gross proceeds at initial Tranche 1 closing. On November 27, 2020, the Company issued to Crowdex a $500,000 Unsecured Convertible Promissory Note in a private placement and received $500,000 of gross proceeds from the offering of the Note. On December 31, 2020, the Company sold 500 shares of Series 1A Preferred Stock to Crowdex in exchange for the cancellation of the Note issued on November 27, 2020. There were no further cash proceeds from this closing. On January 4, 2021, the Company entered into another securities purchase agreement with TubeSolar AG, a developer of photovoltaic thin-film tubes that are assembled into modules to enable additional application opportunities in solar power generation compared to conventional solar modules, particularly in the agricultural sector. TubeSolar, headquartered in Augsburg, Germany, is a publicly traded company listed on the Dusseldorf Stock Exchange of Germany under the ticker code: 9TS.DU. Pursuant to the Series 1A Tranche 2 SPA, the Company sold 2,500 shares of Series 1A Tranche 2 Preferred Stock to TubeSolar and received $2,500,000 of gross proceeds on January 5, 2021.
TubeSolar’s $2,500,000 investment will in the future providing it with a 15% interest in Ascent Solar after taking into account outstanding capital adjustments. Tubsolar stated this move aligns with its “second-source strategy”. More specifically, it brings another source of supply in addition to its existing European supplier for flexible copper indium gallium diselenide (CIGS) PV cells.
TubeSolar AG has taken over the laboratory production of OSRAM/LEDVANCE in Augsburg as a spin-off and acquired the patents from LEDVANCE and Dr. Vesselinka Petrova-Koch. TubeSolar AG has been using this patent-protected technology since 2019 to develop and manufacture photovoltaic thin-film tubes that are assembled into modules and whose properties enable additional application opportunities in solar power generation compared to conventional solar modules. The technology will be used primarily in the agricultural sector, spanning agricultural production areas. In the next few years, it is planned to expand production in Augsburg to an annual production capacity of 250 MW.
ASTI CEO Victor Lee stated: “I am pleased that despite the disruptions conferred by COVID-19, we have completed the full placement of the Series 1A Preferred Stock as part of Ascent’s recent restructuring and recapitalization efforts which began in early 2020. This marks the closure of our Phase I reorganization plan and begins a new era for Ascent Solar. We will continue to strengthen our balance sheet as we ramp up production to serve Tier-1 specialty PV markets in conjunction with satisfying the future demand of TubeSolar. Despite an extraordinarily difficult year in 2020, we are optimistic and look forward to stronger years ahead, as our high-value PV market focus begins to take shape. We will continue to update our shareholders regularly as we make continued progress.”
$ASTI pulled back today because the RSI was overbought. This is healthy, because reset the indicators, so now it can run directly to .30 without needing more pullbacks. This is the loading zone, .065 – .06. Still 500% profit from here, in one – two weeks.
— Dr PennyStock (@Dr_PennyStock) February 10, 2021
For More on ASTI Subscribe Right Now!
ASTI, a pioneer in Flexible Solar Modules is making a powerful run up the charts in recent months from well under a penny in December to recent highs of $0.097 per share. The stock has quickly attracted legions of new shareholders and is transforming into a volume leader in small caps trading $35 million in dollar volume on Wednesday alone. ASTI is ex Nasdaq and we have been reporting on the Company for years; back in 2017 we said of ASTI: “OTC speculators love ex big board stocks for their ready liquidity and proven ability to make spectacular moves once on the bb’s and ASTI certainly has potential; this is a company that manufactures battery and solar integrated phone cases designed for Apple and Samsung smartphones that recently announced record revenues as well as a major breakthrough in power-to-weight ratio for its superlight solar modules.” Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine, and one of TIME Magazine’s 50 best inventions for 2011. The technology represents the cutting edge of flexible power and can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications. Last year the US Department of Energy (DOE) used Ascent Solar modules for two exclusive development projects. Things are looking up for Ascent as Tesla looks to Solar to power its new gigafactory. There are big things happening at ASTI, a Company at the right place at the right time as Solar Energy is currently seeing an enormous global boost. The Company recently received a $2.5 million investment from Bernd Fortsch via Crowdex, a well-known German entrepreneur worth hundreds of millions who has now become the controlling shareholder. Mr. Fortsch has quickly brought on a top-level management team of major international executives including Michael Gilbreth as CFO and Will Clarke as class 2 director. On January 4 ASTI received an additional $2,500,000 investment from publicly traded German Company TubeSolar AG, a developer of photovoltaic thin-film tubes that are assembled into modules to enable additional application opportunities in solar power generation compared to conventional solar modules, particularly in the agricultural sector. ASTI CEO Victor Lee stated: “This marks the closure of our Phase I reorganization plan and begins a new era for Ascent Solar. We will continue to strengthen our balance sheet as we ramp up production to serve Tier-1 specialty PV markets in conjunction with satisfying the future demand of TubeSolar.” Tesla has been looking at Solar to power their new gigafactory. We will be updating on ASTI as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with ASTI.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ASTI either long or short and we have not been compensated for this article.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.
Revolutionizing User Experience and Driving Stock Surge
$onfo in news and float are lit pic.twitter.com/7afKMOfdz2
— …frankyboyz… (@frankyboyz77) May 26, 2023
With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.
To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ONFO just took the elevator to the top!
Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0
— 💎 DBR 💎 (@dbr_land) May 26, 2023
Evaluating Financial Performance
While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.
*says the word "AI" once
* $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2
— Commonstock (@JoinCommonstock) May 26, 2023
Investment Outlook and Future Prospects
Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.
$onfo in news and float are lit pic.twitter.com/Q8eIveRfgd
— …frankyboyz… (@frankyboyz77) May 26, 2023
About MightyDeals.com
Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.
About Onfolio Holdings Inc.
Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.
$ONFO #Ai have you seen this stock? Just came out with a competitive AI software that will fight against the tech kings #microsoft #google
— Don’t Look Down (@M_1Ball) May 26, 2023
Conclusion
Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.
$ONFO – "AI program" is laughable. Check it out on https://t.co/0LdCQCWC28. I searched for "shoes" and flower bouquets showed up. I put in a search for "dogs" and african animals came up.
Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr
— Adam Gefvert, CFA (@Shiningboy) May 26, 2023
We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership
Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
